<DOC>
	<DOC>NCT00411528</DOC>
	<brief_summary>The objective of this study is to assess the response of patupilone plus prednisone compared to docetaxel plus prednisone on prostate specific antigen (PSA) in patients with metastatic hormone refractory prostate cancer. Additionally, this study will assess the response on measureable disease and the effects on patient-reported outcomes.</brief_summary>
	<brief_title>Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epothilone B</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Inclusion criteria: Must be ≥ 18 years of age Confirmed and documented diagnosis of prostate cancer Confirmed and documented evidence of progression of disease (hormone refractory) Low testosterone levels Chemotherapynaïve Exclusion criteria: Recent radiation therapy (within 4 weeks) Known brain metastasis Peripheral neuropathy Active diarrhea Significant illnesses such as heart disease, diabetes, or chronic or uncontrolled infections Allergic reactions to patupilone or docetaxel or prednisone or similar compounds Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Hormone Refractory</keyword>
	<keyword>patupilone</keyword>
	<keyword>docetaxel</keyword>
</DOC>